PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 1
CD19Cell therapy
Systemic Lupus Erythematosus
Phase 1
CD19 (B cells) and PD-1+ pathogenic T cellsCell therapy
Systemic Lupus ErythematosusRheumatoid Arthritis
Preclinical / Unstaged
BCMACell therapy
Multiple Myeloma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.